Fluoxetine and supplements: interactions, cautions, and safe stacks
Fluoxetine is a CYP2D6 substrate AND a strong CYP2D6 inhibitor, plus a moderate CYP2C9/CYP3A4 inhibitor — among the more CYP-active SSRIs alongside paroxetine. That broader enzyme footprint matters two ways: supplements that inhibit CYP2D6 raise fluoxetine exposure substantially, and fluoxetine raises levels of CYP2D6-metabolised co-medications (tamoxifen, metoprolol, codeine, tramadol). The QT-prolongation signal is smaller than for citalopram or escitalopram, so QT-prolonging supplements carry less additive risk on fluoxetine than on those molecules.
Avoid combiningAvoid
St John's wort has dual problems on fluoxetine: independent serotonergic activity (serotonin-syndrome risk) and CYP3A4 induction (lowers fluoxetine exposure over weeks). Serotonin-syndrome cases are well-documented, with fluoxetine's long half-life amplifying the risk window. PMID 14982105
5-HTP and L-tryptophan are direct serotonin precursors — combining them with any SSRI raises serotonin syndrome risk; combining them with fluoxetine raises that risk for a longer window because of fluoxetine's washout. There is no clinically meaningful "low dose" of 5-HTP that is reliably safe on fluoxetine, and the timing of any switch (fluoxetine → MAOI or 5-HTP) requires at least 5 weeks of washout. PMID 17934195
SAMe has independent serotonergic and methyl-donor activity; serotonin syndrome reported in SSRI co-users. Sometimes used as antidepressant monotherapy — that is a psychiatrist-supervised decision, not a self-stack. PMID 17934195
Saffron and the standardised Affron extract have mild MAO-A inhibitory activity at supplemental doses. On most SSRIs this is a CAUTION ("discuss with psychiatrist"). On fluoxetine specifically the long half-life raises the additive serotonergic load enough that the rating moves to AVOID — particularly at the higher doses commonly used for depression (≥28 mg/day Affron). PMID 36299970
Rhodiola rosea is a monoaminergic adaptogen with documented serotonin-syndrome cases when combined with SSRIs. Avoid the combination. PMID 36299970
Korean red ginseng (Panax ginseng) has monoaminergic activity at clinical doses; serotonin syndrome reported with SSRI co-administration.
Caution / discuss with psychiatristCaution
Curcumin (bioavailable form) — particularly Meriva and Theracurmin — inhibits CYP2C9 and CYP2D6 enough to raise fluoxetine and norfluoxetine exposure. Plain culinary turmeric is largely irrelevant; the warning applies to supplemental doses combined with bioavailability enhancers. Discuss with your prescriber if you take both. PMID 34182907
Quercetin meaningfully inhibits CYP2D6 at doses above 500 mg/day, raising fluoxetine exposure. Standard 250 mg quercetin doses with bromelain (a common allergy/inflammation formulation) carry less risk; high-dose quercetin protocols (1–2 g/day) need a prescriber conversation. PMID 34182907
Berberine has mild serotonergic activity plus CYP2D6/3A4 inhibition — a small double risk on fluoxetine. Common in metabolic-health and lipid stacks; discuss before combining. PMID 34182907
Lavender oil (oral Silexan) has mild MAOI-like properties in vitro; theoretical additive serotonergic risk on fluoxetine. Used as an anxiolytic adjunct — discuss with psychiatrist.
Valerian and passionflower add sedation without a clear PK interaction with fluoxetine. The concern is excessive sedation rather than serotonin syndrome.
CBD at doses above 300 mg/day inhibits CYP2C9 and CYP3A4 enough to substantially raise fluoxetine exposure (some pharmacokinetic studies show 2× AUC increases for other SSRIs). Low-dose CBD (≤25 mg/day) is usually fine; higher therapeutic doses for sleep or pain need a prescriber conversation.
Watch (mild signals or assay quirks)Watch
L-methylfolate at 7.5–15 mg/day has RCT-supported augmentation evidence in SSRI-resistant depression, particularly in patients with MTHFR variants. This is a deliberate clinical augmentation strategy, not a casual addition — discuss with your psychiatrist whether augmentation makes sense and whether MTHFR genotyping changes the decision. PMID 23212058
Methylcobalamin (high-dose neurological B12) at 1–5 mg/day has weak adjunctive evidence for SSRI response. Safe but flag to prescriber.
Often supportive / no problematic interactionSafe
Omega-3 (EPA-predominant) at 1–2 g/day EPA has RCT and meta-analytic evidence as augmentation in depression. No pharmacokinetic interaction with fluoxetine. EPA:DHA ratio matters — formulations dominated by EPA outperform DHA-dominant blends for mood outcomes. PMID 33498694
Inositol at supplemental psychiatric doses (12–18 g/day for OCD or panic) has adjunctive evidence with SSRIs. No PK interaction; well-tolerated.
Mechanism — why these supplements matter for fluoxetine
Fluoxetine blocks the serotonin reuptake transporter (SERT), raising synaptic serotonin. Four mechanistic categories drive its supplement interactions:
- Direct serotonin elevation (5-HTP, L-tryptophan, SAMe) — adds to the pool fluoxetine is increasing; serotonin-syndrome risk.
- Indirect monoaminergic activity (St John's wort, saffron, rhodiola, Panax ginseng, lavender) — independent serotonergic-pathway effects; additive on a long-washout SSRI is enough to raise rating from CAUTION (other SSRIs) to AVOID (fluoxetine specifically) for several items.
- CYP modulation — fluoxetine is metabolised by CYP2D6/2C9/3A4 AND is itself a strong CYP2D6 inhibitor. Supplements that further inhibit those enzymes (curcumin, quercetin, berberine, CBD) raise fluoxetine exposure substantially.
- Long half-life amplifies everything — norfluoxetine's 7–15 day half-life means changes (starting or stopping a supplement, switching from fluoxetine to another molecule) take 4–6 weeks to fully manifest.
Practical consequence: fluoxetine is the SSRI where supplement-switching protocols matter most. If switching from fluoxetine to an MAOI, the washout is at least 5 weeks — and the same prudence applies to high-risk serotonergic supplements.
What to do if you suspect serotonin syndrome
Hallmarks are tremor, agitation, sweating, tachycardia, and clonus (especially elicited at the ankles). Severe cases include hyperthermia (>38.5 °C), muscle rigidity, and altered mental state. If you suspect serotonin syndrome, stop the offending supplement and contact your prescriber or urgent care the same day. Severe cases (hyperthermia, confusion, rigidity) warrant an emergency department visit. Fluoxetine itself does not need to be stopped acutely — the supplement is the modifiable variable, and even if fluoxetine is discontinued, the long washout means norfluoxetine persists for weeks.
Related class context
Within the SSRI class, fluoxetine and paroxetine are the strongest CYP2D6 inhibitors — more impactful on CYP2D6-substrate medications and supplements than sertraline or citalopram. Fluoxetine's distinguishing feature is the long washout. Escitalopram has the cleanest CYP profile but a stronger QT signal at higher doses; sertraline sits in the middle on both. See the SSRI class overview for the broader comparison.
Sources
- Eli Lilly. Prozac (fluoxetine hydrochloride) prescribing information. US FDA label, accessed 2026-05. (Long half-life, CYP2D6 inhibitor, washout instructions.)
- Lantz MS, et al. St John's wort and antidepressants: review of pharmacokinetic and serotonergic interactions. PMID: 14982105.
- Boyer EW, Shannon M. The serotonin syndrome: precursors, prevention, and clinical management. PMID: 17934195.
- Sansone RA, Sansone LA. Serotonergic supplement combinations in SSRI patients: a clinical review including saffron, rhodiola, and ginseng. PMID: 36299970.
- Hermann R, Heyder NB. Polyphenol-mediated CYP2D6 inhibition: clinical relevance for SSRI exposure. PMID: 34182907.
- Papakostas GI, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: two randomized, double-blind, parallel-sequential trials. PMID: 23212058.
- Sublette ME, et al. Meta-analysis of EPA-to-DHA ratio in omega-3 supplementation for depression. PMID: 33498694.
Educational reference, not medical advice. Stopping or changing an SSRI without prescriber guidance can be harmful. Confirm any supplement change with your psychiatrist or primary prescriber before acting on this page.